NEW YORK, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. announces to investors that it is investigating potential claims on behalf of stockholders of United Community Financial Corp. UCFC, Highlands Bankshares, Inc. HLND, MB Bancorp, Inc. MBCQ, and Ra Pharmaceuticals, Inc. RARX. Additional information about each potential action can be found at the link provided.
United Community Financial Corp. UCFC
Buyer: First Defiance Financial Corp.
Pursuant to the proposed transaction, announced on September 9, 2019 and valued at $473 million, United Community shareholders will receive 0.3715 shares of First Defiance common stock for each share of United Community common stock owned. The investigation focuses on whether United Community and its board of directors violated the federal securities laws and/or breached their fiduciary duties to the Company's shareholders by failing to conduct a fair process and whether and by how much the proposed transaction undervalues the Company.
To learn more about the United Community investigation go to: https://bespc.com/ucfc/.
Highlands Bankshares, Inc. HLND
Buyer: First Community Bankshares, Inc.
Pursuant to the proposed transaction, announced on September 11, 2019 and valued at $91 million, Highlands shareholders will receive 0.2703 shares of First Community common stock for each share of Highlands common stock owned. The investigation focuses on whether Highlands and its board of directors violated the federal securities laws and/or breached their fiduciary duties to the Company's shareholders by failing to conduct a fair process and whether and by how much the proposed transaction undervalues the Company.
To learn more about the Highlands investigation go to: https://bespc.com/hlnd/.
MB Bancorp, Inc. MBCQ
Buyer: BV Financial, Inc.
Pursuant to the proposed transaction, announced on September 6, 2019 and valued at $31 million, MB Bancorp shareholders will receive $15.85 in cash for each share of MB Bancorp common stock owned. The investigation focuses on whether MB Bancorp and its board of directors violated the federal securities laws and/or breached their fiduciary duties to the Company's shareholders by failing to conduct a fair process and whether and by how much the proposed transaction undervalues the Company.
To learn more about the MB Bancorp investigation go to: https://bespc.com/mbcq/.
Ra Pharmaceuticals, Inc. RARX
Buyer: UBC SA
Pursuant to the proposed transaction, announced on October 10, 2019 and valued at $2.1 billion, Ra Pharma shareholders will receive $48 in cash for each share of Ra Pharma common stock owned. The investigation focuses on whether Ra Pharma and its board of directors violated the federal securities laws and/or breached their fiduciary duties to the Company's shareholders by failing to conduct a fair process and whether and by how much the proposed transaction undervalues the Company.
To learn more about the Ra Pharma investigation go to: https://bespc.com/rarx/.
Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information about Bragar Eagel & Squire, P.C. please go to www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contacts
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Alexandra Raymond, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
